Kite Pharma Inc. (KITE) 57.56 $KITE Juno Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Kite Pharma Inc. (KITE) 57.56 $KITE

Juno Therapeutics Gets Lift From Cancer Test Results
at Investor's Business Daily - Tue Apr 21, 1:57PM CDT
Juno Therapeutics' (JUNO) stock rebounded Tuesday as the company reported "highly encouraging" results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)

Kite Pharma Commends Honors Conferred to Drs. Owen Witte and Steven A. Rosenberg at the 2015 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 21, 12:30PM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Owen Witte, M.D., director of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research at UCLA, is being honored at this year's AACR conference as he receives the prestigious G.H.A. Clowes Memorial Award. In addition, Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI), has been inducted into the 2015 Class of Fellows of the AACR Academy. Dr. Witte is a scientific founder of Kite Pharma, serving on Kite's Scientific Advisory Board, and Dr. Rosenberg is a special advisor to Kite.
KITE: 57.56 (-1.43)

Earnings Insights - Kite Pharma
PR Newswire - Tue Apr 21, 8:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64)

Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 20, 5:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech upstarts Juno Therapeutics and ...
ZIOP: 10.88 (+0.03), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)

AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing
EP Vantage - at Seeking Alpha - Mon Apr 20, 3:58PM CDT
For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early...
KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)

Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data
at The Street - Mon Apr 20, 9:22AM CDT
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68)

NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma
GlobeNewswire - Mon Apr 20, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the expansion of manufacturing services under an existing Services Agreement between its wholly-owned subsidiary, PCT, and Kite Pharma, Inc. (Nasdaq:KITE) (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer.
KITE: 57.56 (-1.43), NBS: 2.88 (+0.06)

Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors
at The Street - Sun Apr 19, 11:45AM CDT
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)

The Top 5 Best IPO Performers in the Last Year
at The Street - Thu Apr 16, 2:56PM CDT
These are the top five best IPO performers in the last 12 months.
RDUS: 41.90 (-0.48), KITE: 57.56 (-1.43), CYBR: 65.53 (-0.84), ONCE: 64.79 (-0.25), ATRA: 63.79 (+7.64)

Etsy, Virtu Price High As IPOs Finally Wake Up
at Investor's Business Daily - Wed Apr 15, 6:45PM CDT
The 2015 IPO market is finally starting to pick up the pace after a relatively sleepy start. Etsy (ETSY), an e-commerce site for handmade goods and vintage items, was one of three notable initial public offerings that priced high in their expected...
XBIT: 27.55 (+0.18), VIRT: 21.81 (-0.54), ADRO: 38.17 (-0.50), KITE: 57.56 (-1.43), PRTY: 20.65 (-0.22), CDTX: 14.94 (-0.11), JUNO: 55.72 (-0.68), ETSY: 25.12 (-0.63)

Critical Alerts For GW Pharmaceuticals, Avon Products, 58.com, Box and Kite Pharma Released By InvestorsObserver
PR Newswire - Wed Apr 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GWPH, AVP, WUBA, BOX and KITE.
WUBA: 75.56 (+3.20), AVP: 8.81 (-0.07), BOX: 18.29 (+0.37), KITE: 57.56 (-1.43), GWPH: 113.04 (-0.05)

Why Kite Pharma (KITE) Could Shock the Market Soon - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 8:00AM CDT
Kite Pharma has seen a small negative price movement but large positive earnings estimate revisions make it an unappreciated stock that might have potential for gains
KITE: 57.56 (-1.43)

Celldex Therapeutics Pushes Forward With Varlilumab And Further Proves Its Worth
Investing Healthcare - at Seeking Alpha - Tue Apr 14, 10:05AM CDT

KITE: 57.56 (-1.43), CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21), ONTY: 1.80 (+0.03)

Heat Biologics Is An Opportunity Among Soaring Immunotherapy Biotech Valuations
Sharon di Stefano - Seeking Alpha - Tue Apr 14, 8:20AM CDT
Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox...
HTBX: 7.71 (-0.64), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), CLLS: 31.30 (-0.91), SPPI: 5.98 (+0.04), JUNO: 55.72 (-0.68), BMY: 66.60 (-0.21)

Amgen Upgraded to Strong Buy, Perfect for Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 2:27PM CDT
On Apr 11, Zacks Investment Research upgraded Amgen Inc. (AMGN) to a Zacks Rank #1 (Strong Buy); is it in your portfolio?
CYTK: 7.29 (-0.09), CBM: 42.07 (-0.65), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64)

Immunotherapy: Unleashing The Immune System To Decimate Cancer
ARK Investment Management - at Seeking Alpha - Sat Apr 11, 2:51AM CDT
By James Bannon, Analyst: Genomics For more than a century, surgery and poison have been the antidotes to cancer. When tumors are discovered, doctors decide whether or not to remove them surgically. With or without surgery, doctors typically...
KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)

Kite Pharma to Present at the 2015 Jefferies Immuno-Oncology Summit in Boston
GlobeNewswire - Fri Apr 10, 7:00AM CDT
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present a company overview at the 2015 Jefferies Immuno-Oncology Summit in Boston. The presentation will take place on Wednesday, April 15, 2015, at 8:10 a.m. EDT.
KITE: 57.56 (-1.43)

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.80 (-0.03), NBS: 2.88 (+0.06), OSIR: 16.35 (-0.10), BCLI: 4.29 (-0.09), MDVN: 128.88 (+0.29), INO: 10.39 (-0.09), CYTX: 0.96 (-0.09), STEM: 0.82 (-0.06), JUNO: 55.72 (-0.68), ATHX: 1.34 (+0.01), CUR: 1.96 (-0.04), BLUE: 136.49 (+1.22), VRTX: 132.85 (+0.65), AMGN: 169.10 (+0.64), KERX: 11.52 (-0.15), OMER: 24.41 (-0.15), KITE: 57.56 (-1.43), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15)

Another IPO Filed In Hot Cancer Immunotherapy Field
at Investor's Business Daily - Tue Apr 07, 12:55PM CDT
Adaptimmune Therapeutics has filed for an initial public offering, adding another company to one of the hottest sectors in the biotech field. U.K.-based Adaptimmune Therapeutics plans to raise up to $150 million and list on the Nasdaq under the...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)

Kite Pharma Announces Publication in Science of Cancer Immunotherapy Articles Authored by Lead Collaborators at the National Cancer Institute and the Netherlands Cancer Institute
GlobeNewswire - Mon Apr 06, 7:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced articles being published in the current issue of Science, one article by the Company's Cooperative Research and Development Agreement (CRADA) collaborators at the National Cancer Institute (NCI) and the second article by the Netherlands Cancer Institute (NKI). The first article, "Adoptive Cell Transfer as personalized immunotherapy for human cancer," was authored by Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the NCI, and his colleague Nicholas P. Restifo, M.D., Senior Investigator at NCI's Surgery Branch. The second article, "Neoantigens in cancer immunotherapy," was written by Professor Dr. Ton N. M. Schumacher, Ph.D., Deputy Director of NKI, and Robert D. Schreiber, Ph.D., Director, Center for Human Immunology and Immunotherapy Programs, at Washington University School of Medicine. Professor Schumacher also serves as Chief Scientific Officer of Kite Pharma EU.
KITE: 57.56 (-1.43)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading